| Literature DB >> 27270029 |
Alex Cortez1, Yongkai Li1, Andrew T Miller1, Xiaoyue Zhang1, Kathy Yue1, Jillian Maginnis1, Janice Hampton1, De Shon Hall1, Michael Shapiro1, Bishnu Nayak1, Ugo D'Oro2, Chun Li1, David Skibinski2, M Lamine Mbow3, Manmohan Singh3, Derek T O'Hagan3, Michael P Cooke1, Nicholas M Valiante3, Tom Y-H Wu1.
Abstract
Small molecule Toll-like receptor 7 (TLR7) agonists have been used as vaccine adjuvants by enhancing innate immune activation to afford better adaptive response. Localized TLR7 agonists without systemic exposure can afford good adjuvanticity, suggesting peripheral innate activation (non-antigen-specific) is not required for immune priming. To enhance colocalization of antigen and adjuvant, benzonaphthyridine (BZN) TLR7 agonists are chemically modified with phosphonates to allow adsorption onto aluminum hydroxide (alum), a formulation commonly used in vaccines for antigen stabilization and injection site deposition. The adsorption process is facilitated by enhancing aqueous solubility of BZN analogs to avoid physical mixture of two insoluble particulates. These BZN-phosphonates are highly adsorbed onto alum, which significantly reduced systemic exposure and increased local retention post injection. This report demonstrates a novel approach in vaccine adjuvant design using phosphonate modification to afford adsorption of small molecule immune potentiator (SMIP) onto alum, thereby enhancing co-delivery with antigen.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27270029 DOI: 10.1021/acs.jmedchem.6b00489
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446